Payment overview · 2025
General Payments
$49.33
2 reported records · 2 companies
Healthcare provider profile · identity verified
Richard H. Harding, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MANCHESTER, CT · NPI 1407823966
Verified facts
What the public records show
CMS Open Payments records show Richard H. Harding, M.D. received $49.33 in general payments during 2025 across 2 reported records.
Exact Sciences Corporation accounted for 69.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.48 | 69.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.85 | 30.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.33 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.48 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 521 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 72 |
| Lisinopril | Lisinopril | 220 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 60 |
| Tramadol Hcl | Tramadol Hcl | 208 | 37 |
| Lorazepam | Lorazepam | 200 | 45 |
| Alprazolam | Alprazolam | 178 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 39 |
| Omeprazole | Omeprazole | 143 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 47 |
| Gabapentin | Gabapentin | 142 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 41 |
| Losartan Potassium | Losartan Potassium | 130 | 40 |
| Simvastatin | Simvastatin | 126 | 35 |
| Metformin Hcl | Metformin Hcl | 116 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 22 |
| Metformin Hcl Er | Metformin Hcl | 90 | 23 |
| Ozempic | Semaglutide | 85 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 21 |
| Trazodone Hcl | Trazodone Hcl | 72 | 23 |
| Allopurinol | Allopurinol | 71 | 16 |
| Telmisartan | Telmisartan | 71 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 12 |
| Sertraline Hcl | Sertraline Hcl | 66 | 19 |
| Mirtazapine | Mirtazapine | 65 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 12 |
| Eliquis | Apixaban | 60 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 12 |
| Carvedilol | Carvedilol | 57 | 20 |
| Meloxicam | Meloxicam | 57 | 13 |
| Furosemide | Furosemide | 54 | 16 |
| Bupropion Xl | Bupropion Hcl | 53 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Atenolol | Atenolol | 49 | 15 |
| Famotidine | Famotidine | 49 | 11 |
| Jardiance | Empagliflozin | 49 | 13 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Methadone Hcl | Methadone Hcl | 48 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 27 |
| Clonazepam | Clonazepam | 46 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Irbesartan | Irbesartan | 42 | 13 |
| Montelukast Sodium | Montelukast Sodium | 42 | 14 |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | 14 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 11 |
| Potassium Chloride | Potassium Chloride | 36 | 14 |
| Finasteride | Finasteride | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 20 |
| Januvia | Sitagliptin Phosphate | 33 | 12 |
| Xanax | Alprazolam | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Prednisone | Prednisone | 31 | 25 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 11 |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Diazepam | Diazepam | 22 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Xtampza Er | Oxycodone Myristate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 17 |
| Glipizide | Glipizide | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Glyburide | Glyburide | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Baclofen | Baclofen | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.33 · 2 records | Exact Sciences Corporation | Cologuard Collection Kit, ELIQUIS, NURTEC ODT | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error